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The biopsy pathology of non-coeliac enteropathy
Tropical sprue (TS) is a malabsorption syndrome of
presumed infectious aetiology that affects residents of
(or visitors to) the tropics. The histological changes of
TS are similar to those of coeliac disease, with
increased intraepithelial lymphocytes being central to
both. Unlike in coeliac disease, however, a completely
flat small bowel biopsy is uncommon in TS. TS typi-
cally involves the terminal ileum, whereas coeliac dis-
ease does not. Small intestinal bacterial overgrowth
(SIBO) has been defined as an increase in number
and/or a change in the type of bacteria in the upper
gut. Conditions that predispose to SIBO are largely
those that decrease or interfere with small bowel
motility. The mucosal histology is variable, and may
include modest villous blunting accompanied by
increased lamina propria and epithelial inflammation.
Autoimmune enteropathy (AE) is a family of rare dis-
eases that share common themes such as immunode-
ficiency states and autoantibodies. AE cases typically
have marked villous atrophy similar to that in fully
developed coeliac disease, but they lack the intense
surface epithelial lymphocytosis. Apoptosis and lym-
phocyte infiltration at the base of the crypts, crypt
abscesses and cryptitis are also seen. Patients with
anti-goblet cell antibodies can have a lack of goblet
cells, endocrine cells, and Paneth cells.
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Introduction
Most small bowel biopsies are taken to rule out coe-
liac disease and, given that endoscopic biopsies are
screening tests, the vast majority of these biopsies are
normal (an audit of 6 months of small bowel biopsies
at my own institution found that 93% of biopsies
were histologically normal). This article will focus on
non-coeliac causes of enteropathy, which is a small
subset of small bowel biopsy pathology. This subset is
even smaller because drug-induced enteropathy and
enteropathy-associated lymphomas will be covered in
other sections of this journal. Generically speaking,
enteropathy refers to any pathological process of the
intestine. This review article, however, will focus on
non-coeliac disorders that enter into the differential
diagnosis of coeliac disease in small bowel biopsies,
namely bacterial overgrowth, tropical sprue and
autoimmune enteropathy.
Tropical sprue
Tropical sprue (TS) is an intestinal malabsorption
syndrome of unknown but presumed infectious aetiol-
ogy that affects residents of (or visitors to) the tro-
pics.1 The disease has been found to be both endemic
to and epidemic in a wide variety of places located
between 30° north and south of the equator, includ-
ing India, Southeast Asia, West Africa, northern
South America, and several locations in the Carib-
bean.2,3 There are references to a disease similar to
TS dating back to 1600 BC,3,4 but modern medicine
only recognized it during the 1960s, when epidemics
killing as many as 35 000 people occurred in south-
ern India.1,3
Although the exact infectious pathogen or patho-
gens that cause TS remain a mystery, there is
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convincing evidence that TS is indeed an infectious
process (so much so that another name for the condi-
tion is postinfective tropical malabsorption). It occurs
in geographical regions where enteric infections are
common, in some areas it is epidemic, and recovery
after treatment with broad-spectrum antibiotics, as
well as B12 and folate replacement, is usually rapid
and dramatic.1,3,5 It has been shown that overgrowth
of aerobic bacteria occurs in TS patients, and that
these bacteria may be toxin-producing.6,7 Others
have postulated viral or even parasitic infection as a
cause, but to date there are no convincing data on
the actual pathogen responsible.8,9 Although TS is
not a common diagnosis in the USA and Europe, it is
thought to account for up to 40% of malabsorption
cases in Southern Asia.5 The Aw-19 HLA haplotype
series appears to increase the risk of TS, suggesting
that innate immunity may also play a role in disease
pathogenesis.10
The symptoms of TS can be broken down into
acute and chronic phases, and seem to differ between
visitors to the tropics and those indigenous to the
area. In visitors, the onset is often insidious, but
acute diarrhoea with abdominal pain, nausea, and
flatulence, as well as systemic symptoms such as
fever, myalgia, and weakness, may also occur.4 Fat
malabsorption is uniformly present. The chronic
changes of TS typically occur in indigenous popula-
tions, and include not only acute diarrhoea and mal-
absorption, but also secondary folate and B12
deficiencies, which may take 2–4 years to develop.4
These nutritional deficiencies may lead to glossitis,
stomatitis, and megaloblastic anaemia.
The histological changes of TS are very similar to
those of coeliac disease, as an increase in the number
of intraepithelial lymphocytes is central to the pathol-
ogy of both conditions (Figure 1A,B). Unlike in coe-
liac disease, however, a completely flat small bowel
biopsy is uncommon in TS2,11,12 (Figure 1A).
A recent review by Brown et al. found that nine of
12 TS patients had partial villous blunting, whereas
three had normal villous architecture.2 All 12
patients had increased numbers of intraepithelial lym-
phocytes, but none had a flat (Marsh 3C) small bowel
biopsy.2 This same study found that there were signif-
icantly more eosinophils in the lamina propria of duo-
denal biopsies of TS patients than in those of coeliac
disease patients. The distribution of disease is also dif-
ferent between TS and coeliac disease.2,13 Coeliac dis-
ease tends to involve the proximal small bowel
(sparing the terminal ileum), and hence leads to iron
deficiency anaemia, whereas TS involves the entire
small bowel, including the terminal ileum, leading to
B12 and folate deficiencies. It is very uncommon to
find B12 deficiencies in coeliac disease patients. When
comparing duodenal biopsies with terminal ileum
biopsies in the same TS patients, Brown et al. noted
more inflammation and damage in the terminal
ileum.2 This same study also found increased num-
bers of eosinophils and intraepithelial lymphocytes in
colon biopsies in a subset of TS patients.2 Other stud-
ies have found that the earliest changes in TS are
increased numbers of lamina propria mononuclear
cells and intraepithelial lymphocytes, and that these
A
B
Figure 1. Tropical sprue. A, Low-power view of jejunum showing
mild villous blunting with club-shaped villi. B, High-power view
showing large numbers of intraepithelial lymphocytes.
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changes first occur in the jejunum and then subse-
quently involve the ileum.4,14 It may take up to
4 months for villous blunting to develop.4 When B12
deficiencies are present, one may observe megaloblas-
tic changes in the enterocyte nuclei analogous to the
changes seen in the bone marrow of such patients
(enlarged nuclei with decreased mitoses).
For most surgical pathologists, TS is a diagnosis
arrived at after the initial diagnosis of probable
coeliac disease has been proven wrong by negative
serology findings and/or no response to a gluten-free
diet. After all, in a day and age when receiving any
clinical history with a GI biopsy is cause for celebra-
tion, obtaining a relevant travel history is exceedingly
rare.
Bacterial overgrowth (stasis/blind loop
syndrome)
As our understanding of the microbiome has
expanded, so too has our understanding of how
important this normal flora is to the overall health
and function of the GI tract. Normally, the proximal
small bowel has very few bacteria, owing to the low
pH of the gastric juice that continuously assaults
this region. In the jejunum, the motility of the lumi-
nal contents keeps the numbers of bacteria down,
such that up to one-third of normal people have
negative jejunal cultures.15,16 The bacteria that are
present in the proximal small bowel mirror those of
the oropharynx, and include largely aerobes, with
some facultative anaerobes.15 The colon, on the
other hand, has large numbers of bacteria, which
are mostly anaerobes. The terminal ileum has much
higher numbers of bacteria than the jejunum, and
the type of bacteria is a mixture of those found in
the colon and those found in the proximal small
bowel.15
Small intestinal bacterial overgrowth (SIBO) has
been defined as an increase in the number and/or a
change in the type of bacteria in the upper gut.16
The gold standard for diagnosing this is to find ≥105
colony-forming units per millilitre of proximal jejunal
aspiration fluid.16 Others will consider a diagnosis of
SIBO if there are ≥103 colony-forming units of a bac-
terium that typically inhabits the colon.16 The easiest
and least invasive way to test for SIBO is with a
hydrogen breath test.15
Conditions that predispose to SIBO are largely
those that decrease or interfere with small
bowel motility (Table 1). Previous surgery, Crohn’s
disease, systemic sclerosis, neuromuscular disorders,
adhesions, diabetes mellitus and small bowel divertic-
ula are some of the more common causes.15,16 Some
have postulated that increased gastric pH resulting
from proton pump inhibitors could also increase the
risk of SIBO, but that this does not seem to be a
major cause.16,17 Other risk factors include chronic
pancreatitis, chronic liver or kidney disease, AIDS,
coeliac disease, and advanced age.15,16,18 There is
also a risk of developing bacterial overgrowth in ileal
pouches.
Table 1. Conditions associated with bacterial overgrowth
(stasis syndrome)
Motor disturbances
Systemic sclerosis
Familial visceral myopathies and neuropathies
Diabetes mellitus/autonomic neuropathy
Parkinson’s disease
Amyloidosis
Hypothyroidism
Structural abnormalities
Diverticula of small intestine
Strictures and narrowings
Crohn’s disease
Tuberculosis
Adhesions
Surgically isolated segments
Pouches
Afferent limb in gastrojejunostomy
Enteroenterostomy
Miscellaneous
Coeliac disease
Chronic liver disease/cirrhosis
Chronic renal failure
Chronic pancreatitis
Immunodeficiencies
HIV
Common variable immunodeficiency
Advanced age
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The abnormal bacteria lead to both malabsorption
and maldigestion. Injury to the brush border can lead
to decreased disaccharidase activity which, in turn,
can lead to accumulation of increased amounts of
complex sugars for the bacteria to metabolize. This
metabolism leads to increased hydrogen production,
which can be detected in breath testing. The bacteria
can also compete for protein and vitamin B12, leading
to deficiencies in these nutrients.16 In addition, the
bacteria deconjugate bile acids, leading to fat and
vitamin malabsorption. This combination typically
leads to chronic diarrhoea and weight loss.
The mucosal histology is quite variable, such that
it is very difficult, if not impossible, to diagnose SIBO
conclusively in endoscopic biopsy material. A histo-
logical review by Lappinga et al.19 found that over
half of their patients with culture-proven SIBO had
normal biopsies. When abnormalities are present,
there is often a modest degree of villous blunting,
which may be accompanied by an increase in the
number of lamina propria chronic inflammatory cells
(Figure 2A).19,20 Intraepithelial neutrophils and/or
lymphocytes may also be present/increased in num-
ber (Figure 2B).19 These findings are most often pat-
chy and milder than the changes seen in fully
developed coeliac disease; however, they are certainly
in the differential diagnosis of a Marsh 1 lesion.
When reviewing biopsies from cases of SIBO, one
may initially have a feeling that the gestalt is not
quite right, without being able to identify what
exactly is wrong. Appropriate clinical history goes a
long way in helping the pathologist to suggest the
possibility of bacterial overgrowth. In resection speci-
mens, one may find the root cause of the motility
problem that leads to the SIBO, such as systemic scle-
rosis (Figure 2C), small bowel diverticular disease, or
familial visceral myopathy.
Antibiotic therapy is the key to eradicating the
abnormal bacteria and restoring order to the microbi-
ome. The exact type and duration of antimicrobial
therapy depend, to some degree, on the underlying
condition. Patients with longstanding motility disor-
ders may require multiple periodic or long-term
courses of antibiotics.
Autoimmune enteropathy
Autoimmune enteropathy (AE) is a family of rare dis-
eases that share a number of common themes.21–23
Although AE was initially described in children with
intractable diarrhoea that developed in the first few
weeks to months of life, there are well-established
adult-onset cases as well.22–24 These diseases share
the presence of anti-enterocyte antibodies (for the
most part), and in many, if not most, cases are
A
B
C
Figure 2. Bacterial overgrowth in progressive systemic sclerosis
(scleroderma). A, Low-power view of jejunum showing moderate
villous blunting with a somewhat hypercellular lamina propria.
B, Higher-power view showing a mild increase in the number of
intraepithelial lymphocytes. C, High-power view of muscularis
propria showing dense collagen with an absence of smooth muscle
fibres, a manifestation of the underlying collagen vascular disease
and the cause of the bacterial overgrowth.
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accompanied by some form of underlying immunode-
ficiency syndrome.22,23 Five diagnostic criteria have
been proposed: (i) diarrhoea with a duration of
>6 weeks; (ii) malabsorption; (iii) small bowel biopsy
showing some degree of villous blunting with deep
crypt lymphocytosis and apoptosis with minimal sur-
face lymphocytosis; (iv) exclusion of other causes of
villous atrophy, such as coeliac disease; and (v) anti-
enterocyte or anti-goblet cell antibodies.25 Although
one might think that anti-enterocyte antibodies
would be the one steadfast requirement for the diag-
nosis of AE, several studies have found that 13–15%
of patients with AE have negative antibody find-
ings.23,26 In addition, it has been shown that these
autoantibodies are not specific for AE, as patients
with HIV, inflammatory bowel disease and even coe-
liac disease may have them.22 The antibodies will
decrease or disappear with successful treatment of
AE.22 AE patients may have other autoantibodies,
such as anti-parietal cell antibodies, anti-islet cell
antibodies, and antinuclear antibodies.22
Several phenotype–genotype relationships have
emerged. Perhaps the most well-defined of these is
the immune dysregulation, polyendocrinopathy and
X-linkage (IPEX) syndrome. Young male patients with
IPEX have been shown to have germline mutations
in the FOXP3 gene on the X chromosome.27–29 The
FOXP3 gene product is expressed in regulatory
T cells, which play a critical role in immune func-
tion.23 Patients with IPEX syndrome may develop
cytopenias, haemolytic anaemia, type 1 diabetes, ato-
pic dermatitis, thyroiditis, thymic involution, arthritis,
nephritis, and hepatitis.22,23 Given all of these afflic-
tions, it is not surprising that IPEX patients have a
poor prognosis.
Another inherited form of AE is autoimmune poly-
endocrinopathy, mucocutaneous candidiasis and ecto-
dermal dystrophy (APECED) syndrome, which is an
autosomal recessive condition.22,23 Patients typically
present with Candida infections, and then progress to
develop hypoparathyroidism or Addison’s disease, and
possibly autoimmune gastritis, autoimmune hepatitis,
type 1 diabetes, thyroid disease, gonadal dysfunction,
and hair and nail loss.22,23 The genetic defect is in
the AIRE gene, which encodes a transcription factor
affecting T-lymphocyte function.21,22
Other immunodeficiency states have been reported
in patients with AE, including common variable
immunodeficiency and IgA deficiency.30 Mutations in
the ITCH and MLL2 genes have also been reported in
children with AE and other autoimmune disorders.21
Rare cases of adult-onset AE have been
reported.21–23,31–33 These patients typically have
A
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Figure 3. Autoimmune enteropathy. A, Low-power view of duode-
num with complete villous flattening and intense chronic inflam-
mation of the lamina propria. The surface epithelium is largely
intact without many intraepithelial lymphocytes. Note the absence
of goblet cells, Paneth cells, and endocrine cells (this patient had
anti-goblet cell antibodies). B, Higher-power view of crypt bases
showing intraepithelial lymphocytes and apoptotic cells. C, High-
power view of a crypt abscess and dense plasmacytosis of the deep
lamina propria. Adjacent crypts contain apoptotic bodies and infil-
trating lymphocytes.
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severe weight loss and malabsorption, and are ini-
tially thought to have coeliac disease.31 A handful of
cases of AE have been reported in patients with thy-
momas, in keeping with the role of the thymus in
immune regulation.33,34 In my own experience, some
adult patients with AE have been taking the drug
olmesartan, calling into question the diagnosis of AE,
despite these patients having anti-enterocyte antibod-
ies. Perhaps the drug acts as a trigger for initiating
the autoimmune reaction in these patients.
Autoimmune enteropathy patients have intractable
secretory diarrhoea that does not respond to a
gluten-free diet or total parenteral nutrition.35 The
mainstay of therapy is immunosuppression with
agents such as steroids, azathioprine, methotrexate,
mycophenolate, tacrolimus, and cyclosporine.22,25
Newer agents such as infliximab, rituximab and
abatacept have also been used with success.22,25
The histological features of AE have some overlap
with coeliac disease, as both conditions will have vil-
lous blunting and crypt hyperplasia (Figure 3A). In
AE, however, there is not the intense surface intraepi-
thelial lymphocytosis that one sees in coeliac disease.
Instead, AE cases typically have apoptosis and
lymphocyte infiltration at the base of the crypts
(Figure 3B). Crypt abscesses and cryptitis are also
Table 2. Comparison of coeliac disease with non-coeliac enteropathies
Diagnosis Villus morphology Lamina propria Distribution Other findings
Laboratory
findings
Coeliac disease Variable but often
flat. Always has
an increased
number of IELs
Increased number
of plasma cells,
may have an
increased number
of eosinophils and
a few neutrophils
Duodenum > ileum May have
neutrophils in
epithelium in severe
cases. Associated
with lymphocytic
gastritis,
lymphocytic colitis,
and collagenous
colitis
Anti-gliadin,
anti-reticulin and
anti-endomysial
antibodies as
well as anti-TTG
antibodies, HLA
DQ2-positive or
D8-positive
Tropical sprue Mild to moderate
blunting with an
increased number
of IELs
Increased
numbers of
plasma cells and
eosinophils
Ileum > duodenum.
May have colonic
involvement
Atrophic glossitis,
megaloblastic
cytological changes
B12 and folate
deficiencies,
megaloblastic
anaemia
Bacterial
overgrowth
Normal to
moderate
blunting. May
have an increased
number of IELs
and/or
neutrophils
Normal to
increased number
of plasma cells
Anywhere motility
is decreased
Table 1 Hydrogen
breath test
Autoimmune
enteropathy
Usually flat. May
have a slightly
increased number
of IELs. Usually
has cryptitis
(neutrophils)
Increased
numbers of
plasma cells and
lymphocytes
Entire GI tract can
be involved
GVHD-like
apoptosis with
lymphocytes
infiltrating crypt
bases. Lack of
goblet cells,
endocrine cells and
Paneth cells if
anti-goblet cell
antibodies present.
Associated with
immunodeficiency
states and
thymomas
Anti-enterocyte
antibodies in
75%,
anti-goblet cell
antibodies in a
smaller subset.
Some patients
have
anti-parietal cell
antibodies
IEL, Intraepithelial lymphocyte; TTG, tissue transglutaminase.
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seen, and there is often an increase in the number of
lamina propria mononuclear cells (Figure 3C).22,26
Patients with anti-goblet cell antibodies can have a
lack of goblet cells, enteroendocrine cells and Paneth
cells on biopsy (Figure 3A–C).26,36 Many patients will
have involvement of the entire gastrointestinal tract,
and in some instances collagenous enteritis and/or
collagenous colitis may be seen.22,26
Autoimmune enteropathy remains a rare and chal-
lenging diagnosis for both pathologists and clinicians.
On encountering a diffusely inflamed and flattened
small bowel biopsy with cryptitis and/or crypt
abscesses, consideration should be given to the diag-
nosis of AE. The presence of apoptosis and/or lym-
phocytic infiltration at the crypt bases should further
increase the level of suspicion.
Conclusions
In summary, this review of non-coeliac enteropathy
has focused on TS, bacterial overgrowth, and AE. All
three of these entities require clinicopathological cor-
relation in order to differentiate them from coeliac
disease and arrive at the correct diagnosis (Table 2).
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